Improved investigation of portal-hepatic veins by echo-enhanced Doppler sonography.

Microbubbles of air released from a galactose vehicle (Levovist) amplify the intensity of Doppler signals. They survive both pulmonary and systemic capillary passage, leading to echo enhancement in the entire vascular system. The aim of this study was to investigate this agent in patients with liver disease and insufficient Doppler signals. A total of 275 Doppler examinations were performed in 176 patients; 20 of these patients could not be studied conventionally due to bowel gas, obesity or noncompliance. They received Levovist to examine portal or hepatic veins or TIPS patency. Angiography, computed tomography (CT) scan or magnetic resonance tomographic angiography (MRTA) was performed subsequently as a control. After administration of Levovist, portal or hepatic veins and TIPS patency could be unequivocally assessed in 18 of the 20 patients. In two patients, suspected occlusion of the portal vein was disproved because the diagnosis was not confirmed later. Only minor adverse effects were encountered. Echo-enhanced Doppler sonography with Levovist is well tolerated. Further study of the value of Levovist for the assessment of portal-hepatic vessels not amenable to conventional Doppler sonography is justified.

[1]  S. Tarui,et al.  Hepatocellular carcinoma in adenomatous hyperplasia: detection with contrast-enhanced US with carbon dioxide microbubbles. , 1993, Radiology.

[2]  C. McArdle,et al.  Improved sensitivity of colour Doppler flow imaging of colorectal hepatic metastases using galactose microparticles: A preliminary report , 1994, The British journal of surgery.

[3]  W. Castañeda-Zúñiga,et al.  Duplex sonography after transjugular intrahepatic portosystemic shunts (TIPS): normal hemodynamic findings and efficacy in predicting shunt patency and stenosis. , 1995, AJR. American journal of roentgenology.

[4]  F. Moriyasu,et al.  Color Doppler sonography of hepatic tumors with a galactose-based contrast agent: correlation with angiographic findings. , 1994, AJR. American journal of roentgenology.

[5]  L. Bolondi,et al.  Accuracy and reproducibility of portal flow measurement by Doppler US. , 1991, Journal of hepatology.

[6]  K. Schwarz,et al.  Doppler enhancement with SH U 508A in multiple vascular regions. , 1994, Radiology.

[7]  R. Groszmann,et al.  Feasibility spectrum for Doppler flowmetry of splanchnic vessels. In normal and cirrhotic populations. , 1990, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[8]  S. Tanaka,et al.  Re: Color Doppler sonography of hepatic tumors with a galactose-based contrast agent. , 1996, AJR. American journal of roentgenology.

[9]  E. G. Hahn,et al.  Color Doppler ultrasound of liver lesions: Signal enhancement after intravenous injection of the ultrasound contrast agent Levovist® , 1996, Journal of clinical ultrasound : JCU.

[10]  L. Y. Wang,et al.  Percutaneous intravascular ethanol injection of the supplying tumor vessel in the treatment of hepatocellular carcinoma larger than 3 cm. , 1996, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[11]  F Forsberg,et al.  Ultrasound contrast agents: a review. , 1994, Ultrasound in medicine & biology.

[12]  S. Takebayashi,et al.  Color Doppler sonography of hepatocellular carcinoma before and after treatment by transcatheter arterial embolization. , 1992, AJR. American journal of roentgenology.

[13]  J. Machi,et al.  Demonstration of arterioportal shunt from tumor thrombus of a hepatocellular carcinoma by carbon dioxide‐enhanced ultrasonography. , 1995, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[14]  C. Bartolozzi,et al.  Hepatocellular carcinoma: use of color Doppler US to evaluate response to treatment with percutaneous ethanol injection. , 1995, Radiology.

[15]  F Lodi Rizzini,et al.  [A high-resolution computed tomographic study of the pulmonary interstitium in systemic autoimmune diseases]. , 1994, La Radiologia medica.

[16]  F Forsberg,et al.  Parenchymal enhancement and tumor visualization using a new sonographic contrast agent. , 1995, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[17]  W. Lees,et al.  Ultrasound contrast agents. , 1994, Clinical radiology.